Dentsply Sirona Inc. (XRAY)
DENTSPLY SIRONA Stock May Gain on the Launch of Primescan 2
XRAY introduces its new-generation intraoral scanner, Primescan 2, to provide effective and efficient care and comfort to patients.
Interpreting Dentsply (XRAY) International Revenue Trends
Explore how Dentsply's (XRAY) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
DENTSPLY SIRONA Inc. (XRAY) Q2 2024 Earnings Call Transcript
DENTSPLY SIRONA Inc. (NASDAQ:XRAY ) Q2 2024 Earnings Call July 31, 2024 8:30 AM ET Company Participants Andrea Daley - Investor Relations Simon Campion - Chief Executive Officer Glenn Coleman - Chief Financial Officer Conference Call Participants Brandon Vazquez - William Blair Dylan Finley - UBS David Saxon - Needham & Company Elizabeth Anderson - Evercore ISI Dan Clark - Leerink Jon Block - Stifel Jeff Johnson - Baird Jason Bednar - Piper Sandler Allen Lutz - BoA Operator Good day and thank you for standing by. Welcome to the DENTSPLY SIRONA Earnings Conference Call.
Dentsply (XRAY) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Dentsply (XRAY) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Dentsply International (XRAY) Q2 Earnings and Revenues Lag Estimates
Dentsply International (XRAY) came out with quarterly earnings of $0.49 per share, missing the Zacks Consensus Estimate of $0.50 per share. This compares to earnings of $0.51 per share a year ago.
Dentsply Sirona Inc Investors Are Encouraged By The Schall Law Firm To Join The XRAY Inquiry
LOS ANGELES, CA / ACCESSWIRE / July 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in DENTSPLY SIRONA Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Dentsply board breached its fiduciary duties to shareholders.
DENTSPLY SIRONA Inc Investors Are Urged By The Schall Law Firm To Participate In The XRAY Inquiry
LOS ANGELES, CA / ACCESSWIRE / July 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in DENTSPLY SIRONA Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Dentsply board breached its fiduciary duties to shareholders.
What's in Store for DENTSPLY SIRONA (XRAY) in Q2 Earnings?
DENTSPLY SIRONA's (XRAY) second-quarter results are likely to reflect growth in the Wellspect Healthcare business and Orthodontic segment amid foreign exchange headwinds.
Dentsply Sirona Inc Investors Are Called Upon By The Schall Law Firm To Join The Xray Inquiry
LOS ANGELES, CA / ACCESSWIRE / July 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in DENTSPLY SIRONA Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Dentsply board breached its fiduciary duties to shareholders.
DENTSPLY SIRONA Inc Investors Are Called Upon By The Schall Law Firm To Join The XRAY Inquiry
LOS ANGELES, CA / ACCESSWIRE / July 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in DENTSPLY SIRONA Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Dentsply board breached its fiduciary duties to shareholders.
Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio Now
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
Analysts Estimate Dentsply International (XRAY) to Report a Decline in Earnings: What to Look Out for
Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
